UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1230-10
Program Prior Authorization/Notification
Medication *Tremfya® (guselkumab)
*This program applies to the subcutaneous formulations of Tremfya
P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 9/2021, 9/2022, 7/2023, 10/2024,
11/2024, 3/2025
Effective Date 5/1/2025
1. Background:
Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of adult patients
with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or
phototherapy, active psoriatic arthritis, moderately to severely active ulcerative colitis, and
moderately to severely active Crohn’s disease.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Tremfya will be approved based on both of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,
Skyrizi (risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq
(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Tremfya will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,
© 2025 UnitedHealthcare Services, Inc.
1
Skyrizi (risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq
(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis
1. Initial Authorization
a. Tremfya will be approved based on both of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,
Skyrizi (risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab),
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Tremfya will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,
Skyrizi (risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab),
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
C. Ulcerative Colitis (UC)
1. Initial Authorization
a. Tremfya will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
© 2025 UnitedHealthcare Services, Inc.
2
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi
(risankizumab)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Tremfya will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi
(risankizumab)]
Authorization will be issued for 12 months.
D. Crohn’s Disease (CD)
1. Initial Authorization
a. Tremfya will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Entyvio
(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Skyrizi
(risankizumab), ustekinumab]
Authorization will be issued for 12 months.
2. Reauthorization
a. Tremfya will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Tremfya therapy
-AND-
© 2025 UnitedHealthcare Services, Inc.
3
(2) Patient is not receiving Tremfya in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Entyvio
(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Skyrizi
(risankizumab), ustekinumab]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits, Step Therapy, and/or Medical Necessity may be in place.
4. Reference:
1. Tremfya [package insert]. Horsham, PA: Janssen Biotech Inc.; September 2024.
Program Prior Authorization/Notification - Tremfya (guselkumab)
Change Control
9/2017 New program
9/2018 Annual review. No changes.
9/2019 Annual review. No changes.
9/2020 Annual review. Changed psoriasis reauthorization duration to 12
months. Added review criteria for psoriatic arthritis. Updated
background and reference.
9/2021 Annual review with no change to coverage criteria.
9/2022 Annual review with no change to coverage criteria. Added Rinvoq to
examples of JAK inhibitors. Added state mandate footnote.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Annual review with no changes to coverage criteria. Updated
reference.
11/2024 Added coverage criteria for ulcerative colitis. Updated background and
reference.
3/2025 Added coverage criteria for ulcerative colitis. Updated background.
© 2025 UnitedHealthcare Services, Inc.
4